Loading clinical trials...
Loading clinical trials...
An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
Conditions
Interventions
Secukinumab
Placebo (Pbo)
Locations
56
United States
Novartis Investigative Site
Portland, Oregon, United States
Novartis Investigative Site
Duncansville, Pennsylvania, United States
Novartis Investigative Site
Jackson, Tennessee, United States
Novartis Investigative Site
Kingsport, Tennessee, United States
Novartis Investigative Site
Spokane, Washington, United States
Novartis Investigative Site
Brussels, Belgium
Start Date
November 6, 2013
Primary Completion Date
March 16, 2018
Completion Date
March 16, 2018
Last Updated
July 30, 2019
NCT01422694
NCT04301128
NCT05961267
NCT03778515
NCT05283096
NCT03092583
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions